CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT02642965
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:39:36.079391+00:00
- Published At
- 2019-12-30T00:00:00+00:00
- Record Updated At
- 2023-09-08
- Results Posted At
- 2019-12-30
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Acute Myeloid Leukemia Post Cytotoxic Therapy", "Recurrent Childhood Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-09-08"- protocolSection.identificationModule.nctId
"NCT02642965"- protocolSection.identificationModule.officialTitle
"A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE1", "PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2019-12-30"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.